Antidepressant effects of
ketamine in depressed patients
by
Berman RM, Cappiello A, Anand A, Oren DA,
Heninger GR, Charney DS, Krystal JH
Abraham Ribicoff Center
Clinical Neuroscience Research Unit
Connecticut Mental Health Center,
New Haven, USA.
Biol Psychiatry 2000 Feb 15; 47(4):351-4

ABSTRACT

Background: A growing body of preclinical research suggests that brain glutamate systems may be involved in the pathophysiology of major depression and the mechanism of action of antidepressants. This is the first placebo-controlled, double-blinded trial to assess the treatment effects of a single dose of an N-methyl-D-aspartate (NMDA) receptor antagonist in patients with depression.Methods: Seven subjects with major depression completed 2 test days that involved intravenous treatment with ketamine hydrochloride (.5 mg/kg) or saline solutions under randomized, double-blind conditions. Results: Subjects with depression evidenced significant improvement in depressive symptoms within 72 hours after ketamine but not placebo infusion (i.e., mean 25-item Hamilton Depression Rating Scale scores decreased by 14 +/- SD 10 points vs. 0 +/- 12 points, respectively during active and sham treatment).Conclusions: These results suggest a potential role for NMDA receptor-modulating drugs in the treatment of depression.

Memantine
NMDA antagonists
Pain and the NMDA receptor
NMDA antagonists for drug users
NMDA antagonists against morphine tolerance
NMDA antagonists, opioid receptors and tolerance
NMDA receptors and opiate-induced neural plasticity

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family